On 26 March 2024, the Australian Senate resolved to establish the Select Committee on Adopting Artificial Intelligence (“Committee”) to inquire into and report on the opportunities and impacts arising out of the adoption of AI technologies in Australia.
The Committee’s inquiry provides an important opportunity for Australian companies to shape the future direction of Australia’s AI-related regulatory reforms as the Government continues to formulate its position on the regulation of AI.
From governments to private investors, big pharma to biotechs, organizations inside and outside the region are reimagining healthcare and life sciences to improve access, outcomes and affordability. This requires capital investment, collaboration and change at levels rarely seen before. In our digital campaign, we explore this dynamic through two main themes and identify six key market opportunities.
With the rapid rise of environmental consciousness in Australia and abroad, consumer-facing businesses are increasingly making claims about the environmental qualities of their products, services and business operations. While the ACCC has had guidance on the practice of “greenwashing” for some time, policing of environmental and sustainability claims has been a core area of focus for the ACCC in the last 12 months.
The new Australian Government promises nearly AUD 1 billion in investments to Medicare and general practices as part of a number of policy commitments to healthcare and aged care initiatives.
On 21 May 2022, Australia elected a new federal government, the Australian Labor Party. As part of its campaign, the newly elected Federal Government committed to a number of healthcare and aged care policy initiatives with a strong focus on improving quality and access to primary care.
How do life sciences companies intend to leverage new and existing sources of growth? Explore the trajectory of life sciences transactions in our latest report.
As digital transformation reshapes business models with different emphases across regions, digitally enabled strategies are helping companies transition from product-only offerings to product-service hybrids, orient to patient mapping, pre-diagnostics solutions and enhancing treatment administration.
This report, the fourth in our Asia Pacific Business Renewal Series, explores how businesses are now fortifying their ESG efforts and pivoting from strategy to action. As businesses integrate ESG action into business renewal, there is an imperative to mitigate risks and pre-empt regulatory and compliance complexities amid uneven recovery and progress across jurisdictional and sectoral landscapes in the region.
This report, the fourth in our Asia Pacific Business Renewal Series, explores how businesses are now fortifying their ESG efforts and pivoting from strategy to action.
Click to read Digital healthcare, a globally booming market, has been catalyzed by the events of COVID-19. In Asia Pacific, in particular, a rapidly expanding population, an empowered and tech-savvy middle class and physician shortage has created the perfect conditions for digital health innovation. A new era of digital healthcare…
The Baker McKenzie Healthcare & Life Science Industry Group presented the first of a series of short webinars sharing legal industry insights and providing practical guidance in the context of today’s evolving world. On 17-18 November 2020, the session focused on a region-by-region view of the evolving compulsory licensing regimes during the COVID-19 pandemic.